Global Antisense & RNAi Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Antisense & RNAi Therapeutics Market Growth (Status and Outlook) 2023-2029

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".

LPI (LP Information)' newest research report, the “Antisense & RNAi Therapeutics Industry Forecast” looks at past sales and reviews total world Antisense & RNAi Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense & RNAi Therapeutics sales for 2023 through 2029. With Antisense & RNAi Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense & RNAi Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Antisense & RNAi Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antisense & RNAi Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense & RNAi Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense & RNAi Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense & RNAi Therapeutics.

The global Antisense & RNAi Therapeutics market size is projected to grow from US$ 937.7 million in 2022 to US$ 1268.5 million in 2029; it is expected to grow at a CAGR of 4.4% from 2023 to 2029.

North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

This report presents a comprehensive overview, market shares, and growth opportunities of Antisense & RNAi Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
RNA Interference
SiRNA
MiRNA
Antisense RNA

Segmentation by application
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.